Humanized monoclonal antibodies have been developed, which target immune checkpoint receptors, including monoclonal antibodies blocking CTLA-4 (Ipilimumab), PD-1 (Pembrolizumab, Nivolumab) and PDL-1 (Atezolizumab, Avelumab and Durvalumab), allowing for immune-driven cancer killing [2]. This evidence concerns the gene CD274 and cancer.